Search This Blog

Wednesday, March 25, 2026

Quoin: FDA may accept single flexible Phase 3 trial of QRX003 for Netherton Syndrome

 

Quoin Pharmaceuticals says FDA may accept single flexible Phase 3 trial of QRX003 for Netherton Syndrome

  • Guidance follows a constructive Type C FDA meeting regarding QRX003 development for Netherton Syndrome.
  • Company now targets completion of Phase 3 enrollment in 2026 and a potential NDA filing in 2027.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)